Hill Research and AI on the Hill open 2026 with a live panel on AI, biometrics, and regulatory accountability

To mark the beginning of 2026, Hill Research, through its AI on the Hill series, is convening leaders from regulatory, biostatistics, legal, and AI-driven CRO communities for the first public webinar of the year. The discussion will examine how AI is reshaping biometrics workflows in clinical development and what accountability will look like as adoption accelerates.

As AI adoption accelerates across the industry, biometrics teams are entering a new phase, one defined not by experimentation, but by accountability. This live panel discussion will focus on what this shift means in practice for statistical programming, quality frameworks, regulatory submissions, and legal readiness as organizations prepare for increased FDA interaction.

Why this discussion matters in 2026

Over the past year, many organizations have experimented with AI in biometrics and clinical data workflows. In 2026, expectations are changing. Sponsors and CROs are increasingly expected to demonstrate not only efficiency gains, but also validation, governance, auditability, and regulatory alignment.

This session will explore how biometrics leaders can navigate this transition—from early experimentation to accountable, submission-ready AI adoption—while preparing for heightened regulatory and legal scrutiny.

What we’ll cover

The discussion will focus on three core themes:

From experimentation to accountability:
Why 2026 marks a turning point for AI adoption in biometrics, and what teams risk losing if they fail to establish baseline workflows, validation, and governance.
The new regulatory and legal reality:
How evolving FDA signals, including Agentic AI and related initiatives, are shaping expectations for AI review, compliance, and cross-functional alignment between biometrics, regulatory, and legal teams.
What AI will actually change in 2026:
Which parts of the biometrics timeline can be shortened today, which use cases are real versus theoretical, and how organizations can decide where AI should—and should not—be applied.

Speakers and moderator

The webinar will feature perspectives from across the biometrics and regulatory ecosystem, including:

Hanrui Zhang, DHT Review Lead, U.S. FDA
Yali Li, Vice President of Biostatistics & Data Management, bioMérieux
Ran He, Founder, THC Lawyers

The discussion will be moderated by:

Louise Liu, PhD, CEO, Hill Research

Event details

Date: January 5, 2026 (Monday)
Time: 2:00–3:00 PM ET
Format: Live public webinar (Zoom Webinar)

Who should attend

This webinar is designed for biostatistics, data science, and clinical development decision-makers and professionals from pharma, biotech, and the broader biometrics community who are preparing for increased AI adoption, and increased accountability, in regulated clinical environments.

Registration

👉 Free register here:
https://us06web.zoom.us/webinar/register/WN_P8HOIpIRQeSTVVBUntzChA

Managing Biometrics in 2026: What Every Biostats Leader Must Know About AI